<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122966</url>
  </required_header>
  <id_info>
    <org_study_id>2009-01-033</org_study_id>
    <nct_id>NCT01122966</nct_id>
  </id_info>
  <brief_title>The Effect of Bevacizumab on the Trabeculectomy</brief_title>
  <acronym>bevazicumab</acronym>
  <official_title>The Effect of Intracameral and Subconjunctival Injections of Bevacizumab in Trabeculectomy With Antimetabolite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to evaluate the additive effect of intracameral and subconjunctival
      injections of bevacizumab in trabeculectomies with other antimetabolites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma filtration surgery is routinely utilized to control intraocular pressure in
      glaucomatous patients. It reduces IOP by creating a fistula between the anterior chamber and
      the subconjunctival space with a filtering bleb. Increased wound healing response affects the
      function and morphology of the filtering bleb, and wound healing involves a series of
      biological events beginning with hemostasis.

      Corticosteroids and antifibrosis agents such as mitomycin C and 5-fluorouracil have been
      employed in trabeculectomy to delay wound healing and hence to improve the success rate of
      surgery by inhibiting inflammation and fibroblastic activity, and the use of these
      antiscarring agents is generally believed to improve the success rate of trabeculectomy.But
      this rate decreased with passing time and thus was not perfect.

      Vascular endothelial growth factor is a pivotal stimulator of angiogenesis because its
      binding to VEGF receptors has been demonstrated to promote endothelial cell migration and
      proliferation in wound healing.Therefore, anti-VEGF agents may potentially modulate wound
      healing following glaucoma filtration surgery.

      The principal objective of this study was to evaluate the additive effect of intracameral and
      subconjunctival injections of bevacizumab in trabeculectomy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>on postoperative 1month</time_frame>
    <description>Intraocular pressure is planned to measure when the patient visit the clinic. All intraocular pressure measurements is acquired by glaucoma specialists, using a slitlamp-mounted Goldmann applanation tonometer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
    <time_frame>on postoperative 6months, 12months, 18months, 24months</time_frame>
    <description>Intraocular pressure is planned to measure when the patient visit the clinic. All intraocular pressure measurements is acquired by glaucoma specialists, using a slitlamp-mounted Goldmann applanation tonometer.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>trabeculectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects who have trabeculectomies with intraocular bevacizumab injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intraocular injections of bevacizumab</intervention_name>
    <description>intracameral and subconjunctival injections</description>
    <arm_group_label>trabeculectomy</arm_group_label>
    <other_name>glaucoma filtering surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  glaucoma patients who have trabeculectomy

        Exclusion Criteria:

          -  patients with the other ocular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changwon Kee, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changwon Kee, M.D., Ph.D.</last_name>
    <phone>82-2-3410-3564</phone>
    <email>ckee@skku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wool Suh, M.D.</last_name>
    <phone>82-2-3410-3564</phone>
    <email>being111@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changwon Kee, M.D., Ph.D.</last_name>
      <phone>82-2-3410-3564</phone>
      <email>ckee@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wool Suh, M.D.</last_name>
      <phone>82-2-3410-3564</phone>
      <email>being111@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Li Z, Van Bergen T, Van de Veire S, Van de Vel I, Moreau H, Dewerchin M, Maudgal PC, Zeyen T, Spileers W, Moons L, Stalmans I. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5217-25. doi: 10.1167/iovs.08-2662. Epub 2009 May 27.</citation>
    <PMID>19474408</PMID>
  </reference>
  <reference>
    <citation>Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology. 2008 Dec;115(12):2141-2145.e2. doi: 10.1016/j.ophtha.2008.06.009. Epub 2008 Aug 9.</citation>
    <PMID>18692246</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Changwon Kee</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>trabeculectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

